Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of ...

Some bacterial species possess an astonishing ability: They use Earth's magnetic field to orient themselves. To better understand this mechanism, the team led by Argovia-Professor Martino Poggio from ...

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...

Good afternoon, and welcome back to the Health Brief newsletter. I’m coming to you today from the Anthem theater in Washington, D.C., where the pharmaceutical industry is convening to discuss the ...

Investing.com -- Compass Pathways Plc (NASDAQ:CMPS) stock surged 33.7% on Tuesday following the announcement of highly statistically significant results from its second Phase 3 trial for COMP360, a ...

Nicolle Russell knows where the buck stops with Trump. Ohio renters deserve real solutions.

His range was like a swinging pendulum of human temperament, allowing him to be bellowing and destructive or discreet and vulnerable - sometimes within a single film or even a single scene.

Including age-gating social media accounts, prohibiting access to weight loss drugs, and allowing adoptees to access their birth certificates ...

Pfizer Inc. today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in ...